R. John Fletcher was named Chairman of the Board of ClearPoint Neuro, Inc. As of November 15, 2026, ClearPoint Neuro, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 21, 2026, naming 1 appointment (Form 8-K, May 21, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like ClearPoint Neuro, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
ClearPoint Neuro, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-21. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as ClearPoint Neuro, Inc. files it.
Also on the record for ClearPoint Neuro, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 3, 2026 | Stake report, Schedule 13G/A, by Bigger Michael | 8.12% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by MAK CAPITAL ONE LLC | 7.8% of the class | 5%+ stakes | Source |
| August 4, 2026 | Stake report, Schedule 13G/A, by Bigger Michael | 7.45% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 7.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by MAK Capital Fund LP | 6.3% of the class | 5%+ stakes | Source |
| April 20, 2026 | Stake report, Schedule 13G/A, by Bigger Michael | 7.54% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 13, 2026 | Stake report, Schedule 13G, by MAK Capital Fund LP | 6.1% of the class | 5%+ stakes | Source |
| February 5, 2026 | Form D, private offering | $17.89M sold | Form D page | Source |
| February 4, 2026 | Stake report, Schedule 13G/A, by Bigger Michael | 7.8% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Bigger Michael | 7.6% of the class | 5%+ stakes | Source |
| August 4, 2025 | Stake report, Schedule 13G/A, by Bigger Michael | 7.7% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs ClearPoint Neuro, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on ClearPoint Neuro, Inc. and the records around it.
ClearPoint Neuro, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Form D filing Feb 2026
- Who owns it
Companies that share a holder
- MAK CAPITAL ONE LLC also filed stake reports on 3 other companies: PERMA FIX ENVIRONMENTAL SERVICES INC (Aug 2026), STANDARD BIOTOOLS INC. (Aug 2026), HEIDRICK & STRUGGLES INTERNATIONAL INC (Nov 2025)
- MAK Capital Fund LP also filed stake reports on 7 other companies: Comstock Inc. (Oct 2026), Autolus Therapeutics plc (May 2026), STANDARD BIOTOOLS INC. (May 2026)
- BIGGER CAPITAL FUND L P also filed stake reports on 13 other companies: Neuraxis, INC (Nov 2026), Dermata Therapeutics, Inc. (Nov 2026), BTC Digital Ltd. (Oct 2026)
Watch ClearPoint Neuro, Inc.
Get an email when ClearPoint Neuro, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ClearPoint Neuro, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ClearPoint Neuro, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ClearPoint Neuro, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-21 | In | Chairman of the Board | 8-K, 2026-05-21 |
Who leads ClearPoint Neuro, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chairman of the Board: R. John Fletcher, appointed (filed 2026-05-21).
New leaders reset buying decisions — get the Full Report on ClearPoint Neuro, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chairman of the Board at ClearPoint Neuro, Inc., with the record behind each one.
Find candidates like Chairman of the Board at ClearPoint Neuro, Inc.Every change, in the filing's words
Appointed: R. John Fletcher, Chairman of the Board
The Board also confirmed the appointment of Mr. Fletcher as Chairman of the Board.
- The annual meeting of the stockholders of ClearPoint Neuro, Inc. (the "Company") was held on May 20, 2026 (the "Annual Meeting").
- At the Annual Meeting, the Company's stockholders voted to approve the adoption of the ClearPoint Neuro, Inc. Seventh Amended and Restated 2013 Incentive Compensation Plan (the "Plan").
- The Company's Board of Directors (the "Board") had previously adopted and approved the Plan, subject to stockholder approval.
- Following the Annual Meeting, the Board appointed the following committee memberships, effective upon the conclusion of the Annual Meeting and the resulting change in Board composition: Audit Committee: Lynnette C. Fallon (Chair), R. John Fletcher, and Timothy T. Richards.
- The Board determined that each member qualifies as independent under Rule 5605(d)(2)(A) of the Nasdaq Marketplace Rules and as a "non-employee director" for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.
- Corporate Governance and Nominating Committee: R. John Fletcher (Chair), Lynnette C. Fallon, and B. Kristine Johnson.
- The Board determined that each member qualifies as independent under Rule 5605(e)(1) of the Nasdaq Marketplace Rules.
Tools for this story
Each opens in a new tab, filled in for ClearPoint Neuro, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
